PDCD1 and neoplasm: Similarly, inhibiting the tumor-released immunomodulatory chemokine CXCR4 in combination with anti-PD1 demonstrated increased overall survival in GBM mouse models along with a decrease in regulatory FOXP3+ T cells and an elevation in inflammatory cytokine levels (IFN-γ/TNF-a) (86).